EpiCept Corporation (EPCT) - 500 Beiträge pro Seite

[panik]

Profile:EpiCept Corporation, a specialty pharmaceutical company, engages in the research, development, and commercialization of pharmaceutical products for the treatment of pain and cancer. Its lead oncology compound, Ceplene, which is used for acute myeloid leukemia is in a Phase III trial. The company’s late-stage analgesic candidates include EpiCept NP-1 Cream, a prescription topical analgesic cream designed to provide relief from the pain of peripheral neuropathies; LidoPAIN SP, which is designed to provide topical delivery of lidocaine to a post surgical or post-traumatic sutured wound; and LidoPAIN BP, a prescription analgesic, designed to provide topical delivery of lidocaine for the treatment of acute or recurrent lower back pain. EpiCept is preparing NP-1 Cream for Phase III clinical trials; and is conducting Phase II trial for LidoPAIN SP. The company’s earlier-stage product candidates include EpiCept MP/DP, a topical spray gel matrix, containing morphine and lidocaine for oral mucositis; LidoPAIN TV for the treatment of tinnitus; and LidoPAIN HM for the treatment of headache pain. EpiCept has completed initial Phase II clinical trials and intends to conduct additional Phase II clinical trials these product candidates. In addition, it develops apoptosis inducers, which include EPC2407, an anticancer drug candidate; EP2167, a compound, whose apoptosis-inducing anti tumor activities are mediated through the transferring receptor; and EP128504, a novel inducer of apoptosis for breast and colorectal cancer cells. The company operates in North America and Europe. It has strategic alliances with Adolor Corporation for the development and commercialization of LidoPAIN SP in North America; and Endo Pharmaceuticals, Inc. for the commercialization of LidoPAIN BP. EpiCept was founded in 1993 and is headquartered in Englewood Cliffs, New Jersey.

http://www.epicept.com/

[panik]

EpiCept Licenses Patent for Bupivacaine in Back Pain to DURECT
Tuesday December 26, 12:05 am ET
- Advances Strategy to Optimize Value of Intellectual Property Assets to Treat Pain -


TARRYTOWN, N.Y., Dec. 26 /PRNewswire-FirstCall/ -- EpiCept Corporation (Nasdaq: EPCT; OMX Stockholm) today announced it entered into a license agreement with DURECT Corporation (Nasdaq: DRRX - News) pursuant to which it has granted DURECT the exclusive, worldwide rights to certain of EpiCept's intellectual property for a transdermal patch containing bupivacaine for the treatment of back pain. Under the terms of the agreement, EpiCept will receive a $1.0 million upfront payment and up to an additional $9.0 million in milestone payments as well as certain royalty payments on future product sales.

(Logo: http://www.newscom.com/cgi-bin/prnh/20020513/NYM112LOGO )

"The signing of this license agreement directly supports our strategy to broaden the application of EpiCept's patent estate in managing back pain beyond the use of lidocaine," remarked Jack Talley, EpiCept President and CEO. "We continue to be focused on the internal development of LidoPAIN® BP, a lidocaine-containing patch for acute back pain, in conjunction with Endo Pharmaceuticals, while we also have granted Endo access to our patents for the development of Lidoderm® as a treatment for chronic back pain. This arrangement with DURECT advances our strategy to maximize the number of opportunities from which we may earn future royalties on the use of our patents. In economic terms, this new arrangement is similar to our arrangement with Endo."

About Back Pain

An estimated 80 percent of adults experience one or more episodes of back pain in their lifetime; the one-year prevalence rate is approximately 15 percent to 20 percent, with some estimates as high as 40 percent. Research from Duke University Medical Center found that the annual cost of treating patients with back pain in the United States exceeds $90 billion, with prescription drugs accounting for approximately $14.1 billion, or more than 15 percent, of that amount.

About EpiCept Corporation

EpiCept is focused on unmet needs in the treatment of pain and cancer. EpiCept has a staged portfolio of pharmaceutical product candidates with several pain therapies in late-stage clinical trials, and a lead oncology compound (for acute myeloid leukemia, or AML) with demonstrated efficacy in a Phase III trial; a marketing authorization application for this compound has been submitted in Europe. EpiCept is based in Tarrytown, N.Y., and its research and development team in San Diego is pursuing a drug discovery program focused on novel approaches to apoptosis.

Forward-Looking Statements

This news release and any oral statements made with respect to the information contained in this news release contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements include statements which express plans, anticipation, intent, contingency, goals, targets, future development and are otherwise not statements of historical fact. These statements are based on EpiCept's current expectations and are subject to risks and uncertainties that could cause actual results or developments to be materially different from historical results or from any future results expressed or implied by such forward-looking statements. Factors that may cause actual results or developments to differ materially include: the risk that Ceplene will not receive regulatory approval or marketing authorization in the EU, the risk that our other product candidates that appeared promising in early research and clinical trials do not demonstrate safety and/or efficacy in larger-scale or later stage clinical trials, the risk that EpiCept will not obtain approval to market any of its product candidates, the risks associated with reliance on additional outside financing to meet its capital requirements, the risks associated with reliance on collaborative partners and others for further clinical trials, development, manufacturing and commercialization of our product candidates; the cost, delays and uncertainties associated with our scientific research, product development, clinical trials and regulatory approval process; our history of operating losses since our inception; competition; litigation; the potential delisting of our common stock by the Nasdaq Global Market; risks associated with the material weaknesses in our internal controls and the outcome of our SOX 404 audit; and risks associated with our ability to protect our intellectual property. These factors and other material risks are more fully discussed in EpiCept's periodic reports, including its reports on Forms 8-K, 10-Q and 10-K and other filings with the U.S. Securities and Exchange Commission. You are urged to carefully review and consider the disclosures found in EpiCept's filings which are available at www.sec.gov or at www.epicept.com. You are cautioned not to place undue reliance on any forward-looking statements, any of which could turn out to be wrong due to inaccurate assumptions, unknown risks or uncertainties or other risk factors.



EPCT - GEN





--------------------------------------------------------------------------------
Source: EpiCept Corporation

[scopus]

New developments from EpiCept outlined recently

Health & Medicine Week - Jan. 08, 2007

New developments from EpiCept outlined recently.

This trend article is an immediate alert from NewsRx to identify the most recent news developments at EpiCept.

Report 1: EpiCept Corporation (EPCT) announced that it has submitted a Market Authorization Application (MAA) to the European Medicines Agency for the Evaluation of Medicinal Products (EMEA) for Ceplene (histamine dihydrochloride), the company's lead oncology product candidate, administered in conjunction with interleukin-2 (IL-2), for the maintenance of first remission in patients with acute myeloid leukemia (AML).

"The filing of an MAA for Ceplene represents a critical step forward in our efforts to fill a specific void of available drug treatment options for AML patients," stated Jack Talley, president and chief executive officer, EpiCept Corporation. "We look forward to working with the European regulatory authorities to obtain a positive opinion for the approval of this important product candidate."

The MAA submission for Ceplene will be reviewed under the E.U. centralized procedure, and if approved, would provide a marketing authorization valid in all E.U. member states. The European Commission has previously granted orphan drug status to Ceplene for use in the treatment of AML.

The pivotal efficacy and safety data for this MAA submission is from a Phase III clinical trial for Ceplene in conjunction with interleukin-2. This study met its primary endpoint of preventing relapse as shown by increased leukemia-free survival for AML patients in remission. The study was conducted in eleven countries and included 320 randomized patients.

The data demonstrated that patients with AML in complete remission who received 18 months of treatment with Ceplene plus low dose interleukin-2 experienced a significantly improved leukemia-free survival compared to the current standard of care, which is no treatment after successful induction of remission. The improvement in leukemia-free survival achieved by Ceplene/IL-2 was highly statistically significant (p=0.0096, analyzed according to Intent-to-Treat).

Even more striking was the benefit observed in patients in their first remission (CR1). In this subgroup, the patients had a 55% improvement in leukemia free survival. This represented an absolute improvement of more than 22 weeks in terms of delayed progression of the disease. This benefit was also highly statistically significant, (p=0.0113) and is the intended patient population (CR1) under consideration for this application. The results of this trial were published in Blood (Blood; The Journal of the American Society of Hematology, volume 108, number 1, July 1, 2006).

Professor Kristoffer Hellstrand, MD, PhD, Sahlgrenska University Hospital, Goteborg, Sweden, an author of the Blood article and responsible for the design of the Phase III study of Ceplene, remarked, "There is a distinctive need for new treatment options to improve long-term leukemia free survival among AML patients. The majority of AML patients in complete remission will experience a relapse of leukemia with a progressively poor prognosis. These study results indicate that Ceplene, combined with low dose interleukin-2, significantly improves long-term leukemia-free survival among these patients."

Report 2: EpiCept Corporation (EPCT) announced that it has appointed Michael C. Chen as the company's vice president for Global Business Development.

He brings to EpiCept a successful track record in business development and deep experience in licensing and acquiring technologies and brand management for the life sciences industry. Prior to joining EpiCept, Chen was executive vice president of sales and marketing at the SpyGlass Group, a healthcare consulting firm. He has also served in several senior management positions at Johnson & Johnson and elsewhere in the pharmaceutical industry.

"We are pleased to have someone of Michael's caliber join EpiCept, and look forward to benefiting from his expertise in licensing and product development negotiation," stated Jack V. Talley, president and chief executive officer of EpiCept.

Prior to the SpyGlass Group, Chen served as executive director of worldwide licensing and acquisitions at Johnson & Johnson, where he structured, negotiated and closed a number of transactions, including several major licenses in the prescription dermatologic market. Additionally, he developed and managed R & D alliances with several worldwide companies. Before Johnson & Johnson, he served as vice president, business development at Synaptic Pharmaceutical Company. At Synaptic, he led the business development efforts, which successfully licensed the company's' proprietary drug targets and secured partners for the development of novel neuro-pharmaceuticals.

Report 3: EpiCept Corporation (EPCT; EPCT) announced operating and financial results for the second quarter ended June 30, 2006.

For the second quarter of 2006, EpiCept's loss attributable to common stockholders totaled $7.3 million, or $.30 per basic and diluted share, versus $3.4 million, or $2.00 per basic and diluted share, for the second quarter of 2005 and $56.6 million, or $2.59 per basic and diluted share, for the first quarter of 2006. Revenues for the second quarter of 2006 totaled approximately $0.2 million. As of June 30, 2006, the company's cash and cash equivalents totaled $7.3 million.

Operating expenses for the second quarter totaled approximately $7.5 million versus $43.1 million for the first quarter of 2006. The company's net cash used in operating activities during the second quarter was approximately $6.5 million, slightly lower than the $7.0 million in the first quarter of 2006. The company expects to make further reductions in its operating cash burn during the balance of the year. Research and development expense in the second quarter increased approximately $0.5 million compared to the first quarter of 2006.

"The second quarter represented a period of steady and continued progress towards our key strategic objectives," stated Jack Talley, president and chief executive officer. "We remain on schedule to file our Marketing Authorization Application for Ceplene for acute myeloid leukemia in Europe later this year, we are completing enrollment in the pivotal scale trial for LidoPAIN SP in Europe, and we are continuing to scale up manufacturing for EpiCept NP-1 in anticipation of the initiation of a Phase III trial at the end of this year.

"We have also made considerable progress towards a future IND filing for EPC2407, our small-molecule apoptosis inducer for the treatment of certain types of cancer. Each of these product candidates represents a significant potential commercial opportunity for our company and we are pleased to have made important strides in advancing these and other product candidates in our pipeline."

Talley continued, "We are also excited to have recently announced the addition of two new members to our management team: Michael Damask, MD, chief medical officer and vice president of medical affairs, and Michael Chen, vice president for global business development. The expertise and experience that these individuals bring to EpiCept will be critical as we advance toward our stated objectives."

EpiCept provided an update on recent progress made with several of its key product candidates:

- Ceplene - a registration-stage compound for the treatment of acute myeloid leukemia (AML), the most common type of leukemia in adults. EpiCept is currently preparing a Marketing Authorization Application (MAA) in Europe for Ceplene. This MAA is anticipated to be filed in the second half of 2006. Ceplene has been granted orphan drug status for the treatment of AML by the European Medicines Agency (EMEA).

- EpiCept NP-1 - a prescription topical analgesic cream designed to provide long-term relief from the pain of peripheral neuropathies, which affect more than 15 million people in the U.S. EpiCept is continuing to scale up the production of NP-1 to prepare for the product candidate's Phase III clinical trials, which are scheduled to commence at the end of this year.

- LidoPAIN SP - the first sterile patch designed to provide sustained topical delivery of lidocaine to a post-surgical or post-traumatic sutured wound in order to relieve post-operative pain and minimize the need for narcotics, NSAIDS or Cox II inhibitors. The pivotal-scale clinical trial for LidoPAIN SP continued during the second quarter. This trial is currently completing enrollment and initial results are expected to be available later this month. Results from the trial, if successful, will form the basis for an approval application in 2007 in Europe. EpiCept's North American partner, Adolor Corporation, recently completed a Phase II trial for LidoPAIN SP in the U.S.

- LidoPAIN BP - A prescription analgesic non-sterile patch designed to provide sustained topical delivery of lidocaine for the treatment of acute or recurrent lower back pain. EpiCept is currently working towards scaling up production of this product candidate in order to commence Phase III clinical trials in close consultation with its partner, Endo Pharmaceuticals.

- EPC2407 - a small-molecule apoptosis inducer discovered at EpiCept. During the second quarter, the Company completed significant preparatory work related to an Investigational New Drug (IND) filing anticipated for this year for the treatment of certain types of cancer.

Financial and operating highlights

The company's general and administrative expense significantly declined by $2.1 million compared to the first quarter 2006. In addition to a $1.7 million reduction in FAS 123R expense, the company benefited from lower legal expense related to outstanding litigation pending against Maxim Pharmaceuticals, and reduced salary and benefit expense resulting from the payment of certain one-time bonuses that occurred during the first quarter 2006.

The company's research and development expense in the second quarter increased approximately $0.5 million compared to the first quarter. EpiCept continued its Phase III clinical trial of LidoPAIN SP in Europe and its preparations to submit Ceplene for marketing approval in Europe for the treatment of AML. The company also initiated manufacturing and commercial scale-up efforts with respect to its EpiCept NP-1 product candidate. Preparation for its intended IND filing for EPC 2407 also continued during the quarter.

In connection with the merger with Maxim Pharmaceuticals, EpiCept recorded a reduction of in-process research and development charges of $0.3 million during the second quarter, reducing total acquired in-process research and development expense to $33.4 million for the six months ended June 30, 2006. During the second quarter, EpiCept revised its estimates for lease termination and legal settlements in connection with the merger with Maxim Pharmaceuticals. A settlement of one litigation matter pending against Maxim Pharmaceuticals was achieved, subject to a court review and approval.

During the second quarter, EpiCept completed the integration of its research and development facilities in San Diego. The company relocated its animal lab facilities to a smaller facility in the region, and reconfigured its research and development facility to allow for shared operation by the company's research and development staff and its San Diego-based general and administrative staff.

This article was prepared by Health & Medicine Week editors from staff and other reports. Copyright 2007, Health & Medicine Week via NewsRx.com.

[scopus]

[nullcheck]

kann man mal das wichtige in deutsch schreiben

[Eurohecht]

heute und gestern ist der kurs hier um jeweils 21 prozent gestiegen?
hat jemand news?
danke.
Eurohecht

[US336]

EPCT (2.58) Mode of Action of EpiCept-Licensed Cancer Compound Profiled at AACR

PR Newswire "US Press Releases "

TARRYTOWN, N.Y., April 20 /PRNewswire-FirstCall/ -- EpiCept Corporation (Nasdaq and OMX Stockholm: EPCT) reported today that studies characterizing a dual mode of action for Azixa(TM), a compound licensed by the Company to Myriad Genetics, Inc. for the treatment of primary and secondary brain tumors, were presented at the annual meeting of the American Association of Cancer Research (AACR) in Los Angeles, California.

(Logo: http://www.newscom.com/cgi-bin/prnh/20020513/NYM112LOGO )

The findings presented by Myriad indicate the potential of Azixa to act as a vascular disrupting agent (VDA), in addition to its previously demonstrated apoptosis inducing capabilities. Vascular disruption of a tumor's endothelium, the inner layer of cells lining a blood vessel, leads to a loss of blood supply to the tumor and subsequent tumor cell death.

Myriad reported that Azixa induced cell death in several primary types of a tumor's endothelium, including micro-vessel endothelial cells. Myriad also reported that in human ovarian cancer xenografts, a single dose of Azixa induced dramatic tumor blood vessel damage and tumor cell death within 24 hours.

"Myriad's findings are another indication of the substantial clinical opportunity that Azixa represents," remarked Jack Talley, President and Chief Executive Officer. "Our agreement with Myriad provides for significant financial benefits for EpiCept, both in the form of milestone payments and sublicensing income as well as future royalties in the event Myriad's development of Azixa continues to progress successfully. In addition, the progress made by Myriad with Azixa also provides further validation of the potential of our earlier-stage oncology programs. Notably, we are continuing with our Phase I trial of EPC2407, a novel, small molecule vascular disruption agent and apoptosis inducer for the treatment of patients with advanced solid tumors and lymphomas, which was discovered through the same Anti-cancer Screening Apoptosis Program (ASAP) responsible for Azixa. EPC2407 is currently dosing its third cohort of patients in an ongoing Phase I study."

Azixa is part of EpiCept's MX90745 series of apoptosis inducers, which was licensed to Myriad as part of an exclusive, worldwide development and commercialization agreement. Under the terms of the agreement, Myriad is responsible for all clinical development and commercialization of compounds from this series. Myriad is currently conducting two Phase II clinical trials for Azixa, one in patients with primary brain cancer and the other in melanoma that has spread to the brain.

About EpiCept's ASAP Technology

Cancerous cells often exhibit unchecked growth caused by the disabling or absence of the natural process of programmed cell death, which is called apoptosis. Apoptosis is normally triggered to destroy a cell from within when it outlives its purpose or it is seriously damaged. One of the most promising approaches in the fight against cancer is to selectively induce apoptosis in

cancer cells, thereby checking, and perhaps reversing, the improper cell growth.

EpiCept's proprietary apoptosis screening technology can efficiently identify new cancer drug candidates and molecular targets that selectively induce apoptosis in cancer cells through the use of chemical genetics and its proprietary live cell high-throughput caspase-3 screening technology. Chemical genetics is a research approach investigating the effect of small molecule drug candidates on the cellular activity of a protein, enabling researchers to determine the protein's function. Using this approach with its proprietary caspase-3 screening technology, EpiCept researchers can focus their investigation on the cellular activity of small molecule drug candidates and their relationship to apoptosis.

This combination of chemical genetics and caspase-3 screening technology allows EpiCept's researchers to discover and rapidly test the effect of small molecules on pathways and molecular targets crucial to apoptosis, and gain insights into their potential as new anticancer agents. This screening technology is particularly versatile and can be adapted for almost any cell type that can be cultured, as well as measure caspase activation inside multiple cell types (e.g., cancer cells, immune cells, or cell lines from different organ systems or genetically engineered cells). This allows researchers to find potential drug candidates that are selective for specific cancer types, which may help identify candidates that provide increased therapeutic benefit and reduced toxicity.

EpiCept has identified several families of compounds with potentially novel mechanisms that induce apoptosis in cancer cells. Several compounds from within these families have progressed to lead drug candidate status with proven pre-clinical efficacies in tumor models and identified molecular targets.

About EpiCept Corporation

EpiCept is focused on unmet needs in the treatment of pain and cancer. EpiCept has a staged portfolio of pharmaceutical product candidates with several pain therapies in late-stage clinical trials, and a lead oncology compound (for acute myeloid leukemia, or AML) with demonstrated efficacy in a Phase III trial; a marketing authorization application for this compound has been submitted in Europe. EpiCept is based in Tarrytown, N.Y., and its research and development team in San Diego is pursuing a drug discovery program focused on novel approaches to apoptosis.

Forward-Looking Statements

This news release and any oral statements made with respect to the information contained in this news release, contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements include statements which express plans, anticipation, intent, contingency, goals, targets, future development and are otherwise not statements of historical fact. These statements are based on EpiCept's current expectations and are subject to risks and uncertainties that could cause actual results or developments to be materially different from historical results or from any future results expressed or implied by such forward-looking statements. Factors that may cause actual results or developments to differ materially include: the risk that Myriad's development of Azixa will not be successful, the risk that Azixa will not receive regulatory approval or achieve significant commercial success, the risk that we will not receive any significant payments under our agreement with Myriad, the risk that the development of our other apoptosis product candidates will not be successful, the risk that our ASAP technology will not yield any successful product candidates, the risk that Ceplene will not receive regulatory approval or marketing authorization in the EU, the risk that our other product candidates that appeared promising in early research and clinical trials do not demonstrate safety and/or efficacy in larger-scale or later stage clinical trials, the risk that EpiCept will not obtain approval to market any of its product candidates, the risks associated with reliance on additional outside financing to meet its capital requirements, the risks associated with dependence upon key personnel, the risks associated with reliance on collaborative partners and others for further clinical trials, development, manufacturing and commercialization of our product candidates; the cost, delays and uncertainties associated with our scientific research, product development, clinical trials and regulatory approval process; our history of operating losses since our inception; competition; litigation; risks associated with our ability to maintain our listing on The Nasdaq Capital Market; risks associated with our ability to have our common stock readmitted to trading on The Nasdaq Global Market; risks associated with prior material weaknesses in our internal controls; and risks associated with our ability to protect our intellectual property. These factors and other material risks are more fully discussed in EpiCept's periodic reports, including its reports on Forms 8-K, 10-Q and 10-K and other filings with the U.S. Securities and Exchange Commission. You are urged to carefully review and consider the disclosures found in EpiCept's filings which are available at www.sec.gov or at www.epicept.com. You are cautioned not to place undue reliance on any forward-looking statements, any of which could turn out to be wrong due to inaccurate assumptions, unknown risks or uncertainties or other risk factors.

*Azixa is a registered trademark of Myriad Genetics, Inc.

EPCT-GEN

SOURCE EpiCept Corporation

[US336]

Antwort auf Beitrag Nr.: 28.918.813 von US336 am 20.04.07 15:17:38

http://www.prnewswire.com/news/index_mail.shtml?ACCT=104&STO…

[US336]

[nullcheck]

Antwort auf Beitrag Nr.: 28.919.102 von US336 am 20.04.07 15:30:24

Bitte um Übersetzung (wesentliche)bin schon über Maxim dabei,super Verlust.Sozusagen Total!Ist Hoffnung angebracht????

mfg

[Eurohecht]

hi nullcheck willkommen im club.
zum glück geht es an der börse nicht nur runter.

[nullcheck]

Antwort auf Beitrag Nr.: 26.522.221 von panik am 28.12.06 15:57:13

erwarte doch etwas mehr von einem Thraederöffner

[nullcheck]

Antwort auf Beitrag Nr.: 28.966.011 von nullcheck am 24.04.07 10:33:14

Na Panik lass mal was hören für einen Leader kommt sehr wenig

[nullcheck]

Antwort auf Beitrag Nr.: 28.984.039 von nullcheck am 25.04.07 10:42:28

Panik versteht mich nicht, kann mal ein anderer was zur Aufklärung beitragen?

[nullcheck]

Antwort auf Beitrag Nr.: 28.962.458 von Eurohecht am 23.04.07 22:59:54

Hi Eurohecht lass du mal was hören, englisch kann ich nicht .Was soll ich machen ,nachkaufen? aber weis nicht wieso, ohne Hintergrund

[Eurohecht]

Hi Nullcheck....

machst ja deinen Nick hier alle Ehre.

Spass beiseite. Ob Du nachkaufst kann ich dir nicht sagen. Das muss Du schon selber wissen.

Die Analysten bei Onvista.de empfehlen die Aktie von EpiCept jedoch mit Strong buy zu kaufen. Und das einheitlich.

Dies kannst du hier nachsehen:

http://aktien.onvista.de/empfehlungen.html?ID_OSI=12186170

Viel Erfolg Eurohecht

[nullcheck]

Geb es wenigstens zu,habe aber was gefunden ohne euch Experten.Zusammenarbeit mit Myriad, Phase 2b Test für Medikament bei Gehirntumor und bedeudente Meilensteinzahlung

[Eurohecht]

nullcheck... heute gehts hier wieder gegen norden.
in frankfurt ist epicept heute um mehr als 11 prozent gestiegen.

[nullcheck]

Nullcheck heist nicht Blind,aber warum gehts gen Norden.Seiten auf deutsch müsste man finden .

[nullcheck]

Bin damals über Global Biotech -Insider (maxim)reingegangen Verlag Boerse-Inside deren Boersenbriefe haben mir eine stange Geld gekostet,jetzt schreiben die kein Stück aus der Hand zu geben.Normal müsste man jetzt raus, lohnt nicht, sind von 2500 E ja nur noch ca 200 E

[Eurohecht]

nullcheck stell doch mal den artikel hier ins board.

[BrauchGeld]

Antwort auf Beitrag Nr.: 29.288.122 von Eurohecht am 13.05.07 10:13:09

Epicept braucht schnellstens geld (cash:6,6mio$) und ob Ceplene im 2H 2007 zugelassen wird ist auch fraglich deshalb ist die Aktie sehr riskant .

Epicept kein Stück aus der Hand geben

07.05.2007
Global Biotech Investing

Endingen (aktiencheck.de AG) - Die Experten von "Global Biotech Investing" empfehlen kein Stück der Epicept-Aktie (ISIN US2942642057 / WKN A0EAY7) aus der Hand zu geben.

Bislang habe man gedacht, dass Azixa das Potenzial besitze, bei Krebszellen den programmierten Zelltod, sprich Apoptose, zu verursachen. In den nun abgeschlossenen Phase II-Studien habe man bei dem Wirkstoff zudem das Potenzial erkennen können, die für die Versorgung der Krebszellen notwendige Blutgefäßausbilung zu unterdrücken. Bei einem derartigen zweifachen Wirkungsmechanismus könne man mit einer deutlich erhöhten Effizienz rechnen. Einen solchen Effekt könne man ansonsten nur in Form von Kombitherapien erzielen, wobei die Gefahr von Interaktionen und Nebenwirkungen wahrscheinlich höher wäre.

Die Experten von "Global Biotech Investing" raten den Anlegern kein Stück der Aktie von Epicept aus der Hand zu geben. (Ausgabe 9 vom 07.05.2007)



http://files.shareholder.com/downloads/EPCT/124980170x0xS950…

[Eurohecht]

Antwort auf Beitrag Nr.: 29.290.870 von BrauchGeld am 13.05.07 14:35:06

danke

[nullcheck]

Antwort auf Beitrag Nr.: 29.288.122 von Eurohecht am 13.05.07 10:13:09

Gebe bei google einfach Epicept ein dann findest du den Artikel
mfg

[nullcheck]

Antwort auf Beitrag Nr.: 29.293.282 von Eurohecht am 13.05.07 17:36:49

Tschuldige, habe den Artikel von brauchgeld erst später gelesen

[nullcheck]

Antwort auf Beitrag Nr.: 29.290.870 von BrauchGeld am 13.05.07 14:35:06

Habe gelesen das Meilensteinzahlungen von Myriad kommen könnten

[nullcheck]

Hab ich richtig gelegen mit B-I. Die würfeln, dann kommt sowas wie Miravant, New Uni,Maxim Liste der Totalverluste ist immens und sehr oft sofort nach Empfehlung,.Schw. blatt

[nullcheck]

Antwort auf Beitrag Nr.: 29.317.981 von nullcheck am 15.05.07 06:58:33

Gerade 1000 st.nachgefasst seh ich die wider?

[nullcheck]

Antwort auf Beitrag Nr.: 29.329.471 von nullcheck am 15.05.07 17:50:41

Schnarchnasenthread, neue Nachricht über azixa muß wohl gut sein( ps newswire) englisch müsste man können

[nullcheck]

Antwort auf Beitrag Nr.: 29.935.989 von nullcheck am 15.06.07 10:58:52

1,90,3500 Stück in Frankfurt bin gespannt auf USA Eröffnung kommt der Durchbruch nach oben???Kann mal einer eine kleine Übersetzung vom wichtigsten reinstellen

[Peederwoogn2]

Antwort auf Beitrag Nr.: 29.936.102 von nullcheck am 15.06.07 11:04:21

geb mal den link bitte

[nullcheck]

Antwort auf Beitrag Nr.: 29.936.163 von Peederwoogn2 am 15.06.07 11:07:20

einfach unter onvista aktienanaly.epicept eingeben unten links

[nullcheck]

Antwort auf Beitrag Nr.: 29.936.252 von nullcheck am 15.06.07 11:12:06

erbarmt sich keiner?

[Peederwoogn2]

Antwort auf Beitrag Nr.: 29.936.642 von nullcheck am 15.06.07 11:34:13

[nullcheck]

Antwort auf Beitrag Nr.: 29.936.778 von Peederwoogn2 am 15.06.07 11:41:02

Veräppeln ?hast du den Artikel gefunden?Wenn du nichts reinschreibst mach wenigstens ein Smily rein

[Peederwoogn2]

Antwort auf Beitrag Nr.: 29.936.642 von nullcheck am 15.06.07 11:34:13

kurz er übersetzt :

MPC-6827 ist beim behandeln vielfacher typen von menschlichen geschwülsten in Tiermodellen wirksam


die ergebnisse werden heute bekannt gegeben.


MYGN steckt da mit drin

[Peederwoogn2]

Antwort auf Beitrag Nr.: 29.936.852 von nullcheck am 15.06.07 11:44:24

sei nett oder ich übersetze die nichts mehr


man bist du nervös

[nullcheck]

Antwort auf Beitrag Nr.: 29.936.927 von Peederwoogn2 am 15.06.07 11:48:40

Danke,bei der letzten guten Nachricht ging es richtig hoch mal abwarten was diesmal passiert

[nullcheck]

Antwort auf Beitrag Nr.: 29.937.007 von nullcheck am 15.06.07 11:53:16

wenn du so alt wärst wie ich ist Nervösität angebracht will von meinen Geld noch was ausgeben. Ist ein ganzer batzen Geld im Spiel (Maxim)

[Peederwoogn2]

Antwort auf Beitrag Nr.: 29.937.127 von nullcheck am 15.06.07 11:58:42

in fra muss man schon 2 € hin blättern 2,66

[Peederwoogn2]

Antwort auf Beitrag Nr.: 29.937.127 von nullcheck am 15.06.07 11:58:42

sieht gut aus übern teich für dich

[nullcheck]

Antwort auf Beitrag Nr.: 29.940.287 von Peederwoogn2 am 15.06.07 14:38:55

Nur in Frankfurt kurs gesehen 2,30 zu 2,10 wie siehts drüben aus? Schreibst was rein wenn,s was neues zu berichten gibt in deutsch,bitte
mfg 0C

[Eurohecht]

Hallo OC,
endlich bewegt sich hier wieder was gell?
mit Maxim hab ich auch noch zu kämpfen. Vielleicht sehen wir ja bald bessere Zeiten.
Salu2, eh

[BrauchGeld]

Epicept braucht geld und solange das nicht erledigt ist wird der kurs immer wieder zurückkommen deshalb würde ich immer gewinne mitnehmen.

Die Nachricht von heute ist kaum von bedeutung da die meisten produkte bei tierversuche erfolgreich sind .


EpiCept Up on Mouse Cancer Data
Friday June 15, 11:24 am ET
EpiCept Shares Rise As Mouse Data Shows Cancer Drug Interferes With Tumor Growth


TARRYTOWN, N.Y. (AP) -- Shares of EpiCept Corp. rose Friday after the small cap drug developer said its experimental cancer treatment was effective in animal models of human cancers.
EpiCept shares rose 39 cents, or 17.9 percent, to $2.57 in midday trading at more than four times their average volume. Shares have traded between $1.37 and $4.89 over the past 52 weeks.

The company said its drug candidate Azixa significantly inhibited the growth of tumors in mice modeled to have human forms of breast, colon, pancreas and ovarian cancers, as well as skin cancer found in mice.

Studies also showed the drug was not affected by cellular proteins known to be involved with traditional resistance to cancer drugs, the company said.

EpiCept said Azixa works by binding to the protein tubulin, interrupting the growth of cancer cells and leading to cell death.

[Eurohecht]

Quelle:

http://aktien.onvista.de/news-filter.html?ID_OSI=12186170&ID…


15.06.2007 06:01:00

New Research Demonstrates Broad Efficacy of Azixa(TM) (MPC-6827) Against Multiple Tumor Types and in Drug Resistant Cell Lines

- Study Results Published in Cancer Research

EpiCept Corporation (Nasdaq and OMX Stockholm: EPCT) today announced the results of scientific studies that (1) demonstrate that Azixa(TM) (MPC-6827) is effective in treating multiple types of human tumors in animal models, (2) reveal a mechanism by which MPC-6827 exerts its effects, and (3) show that MPC-6827 is not affected by cellular proteins known to be involved in cancer drug resistance. The study results appear in the June 15, 2007 edition of Cancer Research, a journal published by the American Association of Cancer Research (AACR).

(Logo: http://www.newscom.com/cgi-bin/prnh/20020513/NYM112LOGO )

"The results of this study demonstrate the potential of Azixa (MPC-6827) to offer significant anti-tumor activity, even in tumors expressing multi-drug resistant phenotypes," remarked Jack Talley, President and Chief Executive Officer. "These data further exemplify the potential of our proprietary Anti-cancer Screening Apoptosis Program, through which this compound was discovered."

The Cancer Research authors describe results showing that MPC-6827 displays significant activity in inhibiting the growth of a broad spectrum of solid tumor lines in athymic nude mice, including human breast, colon, pancreas, ovarian and mouse melanoma. Additional in vitro studies demonstrated that MPC-6827 exerts its effects by binding of tubulin, thereby inhibiting polymerization and leading to cell cycle arrest and apoptosis. Unlike other tubulin-disrupting cancer treatments, MPC-6827 had efficacy against tumor cells that over-expressed the three main protein transporters responsible for multidrug resistance, indicating that MPC-6827 may prove effective against drug resistant tumors in a clinical setting.

MPC-6827 is one of two compounds currently in clinical trials discovered through EpiCept's Anti-cancer Screening Apoptosis Program (ASAP). MPC-6827 is part of the EP90745 series of apoptosis inducers, which was licensed by EpiCept to Myriad Genetics, Inc. as part of an exclusive, worldwide development and commercialization agreement. Myriad recently announced that MPC-6827, which is being developed under the trademark Azixa(TM), has a second mode of action due to vascular disruption activity (VDA). The compound is currently being evaluated in two Phase II human clinical trials, one in patients with primary brain cancer and the other in brain metastases due to melanoma. EpiCept's licensing agreement with Myriad for Azixa includes milestone payments, and sublicensing income as well as future royalties in the event Myriad's development of Azixa continues to progress successfully.

The Cancer Research article, entitled "MPC-6827: A Small Molecule Inhibitor of Microtubule Formation that is Not a Substrate for Multi-Drug Resistance Pumps," was co-authored by researchers at EpiCept Corporation, Myriad Pharmaceuticals, Inc. and the Department of Therapeutic Radiology and Oncology and Department of Internal Medicine, Innsbruck Medical University, Austria.

About EpiCept's ASAP Technology

Cancer cells often exhibit unchecked growth caused by the disabling or absence of the natural process of programmed cell death, which is called apoptosis. Apoptosis is normally triggered to destroy a cell from within when it outlives its purpose or it is seriously damaged. One of the most promising approaches in the fight against cancer is to selectively induce apoptosis in cancer cells, thereby checking, and perhaps reversing, the improper cell growth.

EpiCept's proprietary apoptosis screening technology can efficiently identify new cancer drug candidates and molecular targets that selectively induce apoptosis in cancer cells through the use of chemical genetics and its proprietary live cell high-throughput caspase-3 screening technology. Chemical genetics is a research approach investigating the effect of small molecule drug candidates on the cellular activity of a protein, enabling researchers to determine the protein's function. Using this approach with its proprietary caspase-3 screening technology, EpiCept researchers can focus their investigation on the cellular activity of small molecule drug candidates and their relationship to apoptosis.

This combination of chemical genetics and caspase-3 screening technology allows EpiCept's researchers to discover and rapidly test the effect of small molecules on pathways and molecular targets crucial to apoptosis, and gain insights into their potential as new anticancer agents. This screening technology is particularly versatile and can be adapted for almost any cell type that can be cultured, as well as measure caspase activation inside multiple cell types (e.g., cancer cells, immune cells, or cell lines from different organ systems or genetically engineered cells). This allows researchers to find potential drug candidates that are selective for specific cancer types, which may help identify candidates that provide increased therapeutic benefit and reduced toxicity.

EpiCept has identified several families of compounds with potentially novel mechanisms that induce apoptosis in cancer cells. Several compounds from within these families have progressed to lead drug candidate status with proven pre-clinical efficacies in tumor models and identified molecular targets.

About EpiCept Corporation

EpiCept is focused on unmet needs in the treatment of pain and cancer. EpiCept has a staged portfolio of pharmaceutical product candidates with several pain therapies in late-stage clinical trials, and a lead oncology compound (for acute myeloid leukemia, or AML) with demonstrated efficacy in a Phase III trial; a marketing authorization application for this compound is under review by the European Agency for the Evaluation of Medicinal Products (EMEA). EpiCept is based in Tarrytown, N.Y., and its research and development team in San Diego is pursuing a drug discovery program focused on novel approaches to apoptosis.

Forward-Looking Statements

This news release and any oral statements made with respect to the information contained in this news release, contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements include statements which express plans, anticipation, intent, contingency, goals, targets, future development and are otherwise not statements of historical fact. These statements are based on EpiCept's current expectations and are subject to risks and uncertainties that could cause actual results or developments to be materially different from historical results or from any future results expressed or implied by such forward-looking statements. Factors that may cause actual results or developments to differ materially include: the risk that Myriad's development of Azixa will not be successful, the risk that Azixa will not receive regulatory approval or achieve significant commercial success, the risk that we will not receive any significant payments under our agreement with Myriad, the risk that the development of our other apoptosis product candidates will not be successful, the risk that our ASAP technology will not yield any successful product candidates, the risk that clinical trials for NP-1 will not be successful, that NP-1 will not receive regulatory approval or achieve significant commercial success, the risk that Ceplene will not receive regulatory approval or marketing authorization in the EU, the risk that our other product candidates that appeared promising in early research and clinical trials do not demonstrate safety and/or efficacy in larger-scale or later stage clinical trials, the risk that EpiCept will not obtain approval to market any of its product candidates, the risks associated with reliance on additional outside financing to meet its capital requirements, the risks associated with dependence upon key personnel, the risks associated with reliance on collaborative partners and others for further clinical trials, development, manufacturing and commercialization of our product candidates; the cost, delays and uncertainties associated with our scientific research, product development, clinical trials and regulatory approval process; our history of operating losses since our inception; competition; litigation; risks associated with our ability to have our common stock readmitted to trading on The Nasdaq Global Market; risks associated with prior material weaknesses in our internal controls; and risks associated with our ability to protect our intellectual property. These factors and other material risks are more fully discussed in EpiCept's periodic reports, including its reports on Forms 8-K, 10-Q and 10-K and other filings with the U.S. Securities and Exchange Commission. You are urged to carefully review and consider the disclosures found in EpiCept's filings which are available at www.sec.gov or at www.epicept.com. You are cautioned not to place undue reliance on any forward-looking statements, any of which could turn out to be wrong due to inaccurate assumptions, unknown risks or uncertainties or other risk factors.

--Azixa is a registered trademark of Myriad Genetics, Inc.

EPCT-GEN

Web site: http://www.epicept.com

[nullcheck]

gibt wieder alles ab. Sch.....

[Eurohecht]

frag mich bloss wieso keiner kauft

[nullcheck]

Antwort auf Beitrag Nr.: 29.946.202 von Eurohecht am 15.06.07 19:06:23

Umsatz 1,5 Mio gekauft wird wohl aber der Kurs kommt nicht inne Pötte bei letzten Anstieg ging,s bis 4,80 bin enttäuscht,müsste doch abgehen wie Schmitz Katze.Eure Meinung

[nullcheck]

Antwort auf Beitrag Nr.: 29.952.892 von nullcheck am 16.06.07 14:23:50

Die Aktie ist wie die User dieses Thread,s........!!!!

[nullcheck]

Antwort auf Beitrag Nr.: 30.015.234 von nullcheck am 19.06.07 11:19:56

Brauch geld hat,s begriffen vielleicht als einzigster

[Scheilko]

Antwort auf Beitrag Nr.: 30.015.281 von nullcheck am 19.06.07 11:21:47

Zur Info!

So schlecht kann EPICET also nicht sein!!

http://investing.businessweek.com/businessweek/research/stoc…

[nullcheck]

Antwort auf Beitrag Nr.: 30.023.642 von Scheilko am 19.06.07 18:16:15

Was sollen die denn gemeldet haben .Bei mir zeigt die Adresse Server nicht gefunden .Hauptseite steht die Meldung vom 15.6

[Scheilko]

Antwort auf Beitrag Nr.: 30.028.127 von nullcheck am 19.06.07 21:36:30

Gemeldet haben die heute gar nichts. Ich habe den Insiderhandel von Epicept verglichen mit anderen Gesellschaften in der Biotechnology
gemeint.

**
Insider Transactions by EpiCept Corporation
Past 90 Days The goals of EPCT insiders are aligned with those of shareholders because insiders own an above average percent of this company relative to other companies in the Biotechnology industry. The 75,029 shares they control represents 2.09% of the total outstanding shares. However, although insiders were net buyers of EPCT shares during the last 3 months, they actually bought less than the average quarterly average for the last 2-years. While any insider buys are bullish, this signal is somewhat tempered in its strength.
**

also Insider besitzen bei EpiCept mit 2.09% einen überdurchschnittlichen
Prozentsatz an Aktien im Vergleich mit anderen Biotechfirmen (die letzten 90 Tage betrachtet) .....

zum Vergleich:
Merck & Co. Inc 0.01%
Pfizer Inc. 0.04%
Johnson & Johnson 0.01%,
XOMA Ltd. 0.06%

[nullcheck]

Antwort auf Beitrag Nr.: 30.029.337 von Scheilko am 19.06.07 22:22:02

Mal eine Meldung, hatte auch Insiderkäufe gesucht aber alte Meldungen gesehen aus 2006 waren aber alles Verkäufe. frag aber nicht wo ich das gefunden habe. Auf 1000%.Endlich mal was neues,sollten Ansporn an alle sein

[nullcheck]

Antwort auf Beitrag Nr.: 30.029.745 von nullcheck am 19.06.07 22:43:50

Jetzt gerade erst die Bid und Ask Kurse gesehen in USA das wird Morgen wieder ein Blutbad

[Scheilko]

Antwort auf Beitrag Nr.: 30.029.745 von nullcheck am 19.06.07 22:43:50

Habe doch noch etwas (für mich) neues gefunden.

Epicept wird ab 22. Juni 07 im "Russell Microcap® Index"
vertreten sein.

The Russell family of U.S. indexes is designed to be a comprehensive representation of the investable U.S. equity market. These indexes are value-weighted and include only common stocks belonging to corporations incorporated in the United States and its territories.

Russell Microcap Index measures performance of the microcap segment, representing less than 3% of the U.S. equity market. The Russell Microcap Index includes the smallest 1,000 securities in the small-cap Russell 2000 Index plus the next 1,000 securities.

This is a list of companies which, after applying Russell's objective construction and methodology, will join the Russell Microcap Index at the close of the market June 22. A list of deletions is also available.

Final membership lists for the Russell 3000®, Russell 1000®, Russell 2000®, Russell Midcap® and Russell Microcap will be posted June 25.


http://www.russell.com/Indexes/membership/US/Reconstitution/…

[nullcheck]

Heckenpennerthread!!!

[Peederwoogn2]

Antwort auf Beitrag Nr.: 30.083.917 von nullcheck am 20.06.07 22:42:24

Heckenpennerthread!!!

was dir den in den kopf gestiegen

[nullcheck]

Antwort auf Beitrag Nr.: 30.088.384 von Peederwoogn2 am 21.06.07 10:32:53

Frust und A..hol,sorry

[Peederwoogn2]

Antwort auf Beitrag Nr.: 30.089.094 von nullcheck am 21.06.07 11:10:12

jut sorry ist angenommen

[nullcheck]

Antwort auf Beitrag Nr.: 30.090.360 von Peederwoogn2 am 21.06.07 12:15:58

Wie kommen eigentlich 26 St. Umsatz zustande?

[bernie55]

ALLGEMEINE INFOS zur Zulassung neuer Arzneien


22.06.2007 - 09:28 Uhr

FTD: Das kann ja heiter werden

Die Zulassung neuer Arzneien ist für die Pharmabranche längst keine Kleinigkeit mehr. Regelmäßig lassen die Behörden Hoffnungsträger durchfallen und Börsenträume platzen. Künftig kommt es noch dicker.


Sanofi-Aventis ist fassungslos über die Ablehnung seiner Diätpille Acomplia bei der US-Behörde FDA. Begründung: psychische Nebenwirkungen.

GlaxoSmithKline fürchtet das Aus für das umsatzstarke Diabetesmittel Avandia. Risiko: Herzinfarkt.

Das neue Krebsmittel Vectibix vom weltgrößten Biotechkonzern Amgen findet nicht den Zuspruch der Kontrolleure bei der EU-Behörde Emea. Erklärung: Wirksamkeit zweifelhaft.

Drei Beispiele aus der jüngsten Vergangenheit - eine gemeinsame Wirkung: Aufruhr an der Börse. Die Aktienkurse der betreffenden Konzerne sackten nacheinander auf ein Zweijahrestief. Allen Beteiligten, den Managern, Analysten und Kontrolleuren steckt noch der Skandal um das Schmerzmittel Vioxx in den Knochen. Die Folge für den Hersteller Merck & Co. sowie die Branche waren Tausende Schadensersatzklagen, Imagekrisen und Milliardenverluste. Das mahnte zur Vorsicht. Im Jahr drei nach Vioxx zieht die Politik auf beiden Seiten des Atlantiks die Zügel nun noch fester an.

So feilten am Donnerstag in Washington US-Senatoren an letzten Details für ein Gesetz, das der FDA mehr Einfluss und Geld für zusätzliche Sicherheitskontrollen von Medikamenten gibt. Dazu zahlt die Industrie an die FDA Gebühren von rund 400 Mio. $ jährlich, weitere 225 Mio. $ bringt sie in den kommenden fünf Jahren für die FDA-Observierung von Neueinführungen auf. "Die Nation hat aus den Sicherheitsproblemen mit dem Diabetesmedikament Avandia gelernt", sagte der Vorsitzende des Kongressausschusses, John Dingell, vor wenigen Tagen. Zudem können Verstöße gegen Marketing- und Sicherheitsauflagen mit bis zu 100 Mio. $
Strafe geahndet werden.

Und auch die Emea kann nun härter durchgreifen. Die EU-Kommission hat am 15. Juni eine Verordnung in Kraft gesetzt die Verstöße gegen Emea-Regeln mit hohen Geldbußen ahndet - etwa, wenn Firmen Vorgaben ihrer Arzneimittelzulassungen nicht einhalten, Informationen zur Risikobewertung ihrer Produkte zurückhalten oder deren Nebenwirkungen gar nicht oder erst sehr spät melden.

"Sehr harte Sanktionen"

Die Höchstgrenze der Geldbußen liegt bei fünf Prozent des Jahresumsatzes des betroffenen Zulassungsinhabers. Zulassungsinhaber kann auch eine Konzerntochter sein. "Das dürfte zu ungerechten Bestrafungen führen", sagte Unternehmensanwalt Uwe Fröhlich vom Pharmakonzern Baxter. "Zufälligerweise oder sogar absichtlich kann ein besonders umsatzstarker oder umsatzschwacher Teil eines Konzerns Inhaber der Zulassung sein. Ein Schlupfloch könnten auch Vermarktungspartnerschaften unabhängiger Unternehmen bieten, von denen nur eines die Zulassung hält." Gerechter sei es, die Buße am EU-weiten Umsatz der Arznei festzumachen. "Das sind alles in allem sehr harte Sanktionen", sagt Anwalt Jörg Schickert von der Kanzlei Lovells in München. Er findet manches an der Verordnung unausgereift. "Es gibt noch Schwachstellen, darunter die Frage, wie die Abgrenzung zwischen einzelstaatlichen Strafmaßnahmen und EU-weiten Sanktionen geregelt werden soll."

Das für Zulassungen zuständige Bundesinstitut für Arzneimittel und Medizinprodukte (BfArM) habe in der jüngeren Vergangenheit einige Straf- und Bußgeldverfahren eingeleitet, mit unterschiedlichem Ausgang entsprechend der Beweislage, heißt es auf Anfrage. "Ob es in Zukunft wichtiger sein wird, derartige Instrumentarien zur Verfügung zu haben, lässt sich nur schwer einschätzen", so das BfArM. Die im Arzneimittelgesetz für Ordnungswidrigkeiten vorgesehenen Bußgelder von maximal 25.000 Euro seien vergleichsweise gering.

Die Verordnung (EG) 658/2007 zur Auferlegung von Geldbußen durch die Kommission ist ein neuartiges Sanktionsmittel, das es für von der Emea zugelassene Arzneimittel bislang noch nicht gab. "Die Industrie sollte schnellstmöglich alle Schwachstellen abklopfen und Verfahren aufsetzen, die zukünftig Verstöße vermeiden. Dies sollte auch dokumentiert werden", sagte der Anwalt Schickert.

Emea-Chef Thomas Lönngren zumindest will nie mehr einen Tag wie den 30. September 2004 erleben: Weder der Vioxx-Hersteller Merck & Co. noch die FDA-Kollegen hatten ihn frühzeitig über den geplanten Rückruf der Schmerzpille informiert. Die Börse wusste früher Bescheid als er. "Wir wollen von Konzernen so schnell wie möglich informiert werden", sagte er.



Autor/Autoren: Peter Kuchenbuch

http://www.finanztreff.de/ftreff/news.htm?sektion=topthemen&…

[nullcheck]

Antwort auf Beitrag Nr.: 30.145.255 von bernie55 am 22.06.07 11:42:05

Das betrifft doch alle oder meinst du man sollte auch aus allen Pharmawerten aussteigen

[nullcheck]

Antwort auf Beitrag Nr.: 30.145.468 von nullcheck am 22.06.07 11:52:11

Was ist jetzt schon wieder los, die,,Aktie" ist wie der Thread hier .......!!!!!

[Eurohecht]

Antwort auf Beitrag Nr.: 30.394.630 von nullcheck am 29.06.07 16:24:51

nicht aufregen.
was runtergeht auch wieder nach oben gehen muss.
salu2, eh

[nullcheck]

Antwort auf Beitrag Nr.: 30.394.848 von Eurohecht am 29.06.07 16:36:05

Alles wo EMI (GBI)die Finger drin hat ist reines Glücksspiel rot oder schwarz

[nullcheck]

Antwort auf Beitrag Nr.: 30.395.653 von nullcheck am 29.06.07 17:18:32

Bericht in Finanzen de 10 mill. Dollar raisses Privatplazierung in Warrants usw. Peeder muss mal helfen, weist warum

[BrauchGeld]

Bei kursen um die 2$ ist Epicept ein gutes investment .
Ich denke kommende woche werde ich mir 2000st. ins depot legen.

[nullcheck]

Antwort auf Beitrag Nr.: 30.425.035 von BrauchGeld am 01.07.07 12:39:09

Ist was im Busch ?

[Eurohecht]

Antwort auf Beitrag Nr.: 30.471.027 von nullcheck am 03.07.07 15:50:03

denke es kommen bald wieder news.
und dann ist auch schnell wieder was im busch.
gruss eh

[Scheilko]

Antwort auf Beitrag Nr.: 30.474.428 von Eurohecht am 03.07.07 18:49:28

sind längst da.......

**
EpiCept Accelerates Development of EPC2407 for Cancer
Tuesday July 3, 3:00 am ET
EPC2407 Shows Potent Apoptotic and Tumor Selective Vascular Disruptive Activity (VDA) in Pre-Clinical Studies ........
**

http://biz.yahoo.com/prnews/070703/nytu018.html?.v=94

[nullcheck]

Antwort auf Beitrag Nr.: 30.474.885 von Scheilko am 03.07.07 19:16:40

Warum kaufen die Insider nicht wenn alles so Toll aussieht oder doch nicht?

[nullcheck]

Antwort auf Beitrag Nr.: 30.483.154 von nullcheck am 04.07.07 12:41:57

Ihr seid doch Heckenpenner und Schnarchnasen nehme auch nichts zurück
so long

[Peederwoogn2]

Antwort auf Beitrag Nr.: 30.492.915 von nullcheck am 04.07.07 22:52:28

keine plan von börse aber andere beleidigen wenn mann falsch liegt

[nullcheck]

Antwort auf Beitrag Nr.: 30.516.007 von Peederwoogn2 am 06.07.07 08:35:42

Muss man von der Boerse einen Plan haben?entweder ist man ist auf der richtigen Seite oder nicht. Siehe WLB (VW).Alles Dummschwätzer

[nullcheck]

Antwort auf Beitrag Nr.: 30.516.345 von nullcheck am 06.07.07 09:04:59

Ob ich falsch liege wird sich noch zeigen habe noch ein Paar nachgelegt. Wenn wie bei Miravant die FDA nicht alles kaputt macht oder die Kohle ausgeht könnte das noch was werden

[Scheilko]

Antwort auf Beitrag Nr.: 30.516.452 von nullcheck am 06.07.07 09:12:07

nullcheck was bist du denn für einer? lies dir einmal die boardregeln durch!!
(links von dir wenn du antwortest)


zur info:
http://biotech.seekingalpha.com/article/40185

[Der.Eroberer]

EpiCept Announces Phase III Study of EpiCept(TM) NP-1 for the Treatment of Chemotherapy Induced Peripheral Neuropathy
Monday July 23, 12:01 am ET


TARRYTOWN, N.Y., July 23 /PRNewswire-FirstCall/ -- EpiCept Corporation (Nasdaq and OMX Nordic Exchange: EPCT) today announced that it will study EpiCept(TM) NP-1, its patented topical cream formulation of two FDA-approved drugs, 4% amitriptyline and 2% ketamine, for the treatment of chemotherapy induced peripheral neuropathy (CPN) in the ATTRACT-CPN Phase III Study (Assessment of Topical Treatment Response with Amitriptyline and Ketamine: Combination Trial in Chemotherapy Peripheral Neuropathy). The study will be conducted within a network of approximately 25 sites under the direction of the National Cancer Institute (NCI) funded Community Clinical Oncology Program (CCOP).


Peripheral neuropathy, a painful condition caused by damage to the nerves in the peripheral nervous system, affects over 15 million people in the United States. CPN is the result of the toxicity of a number chemotherapeutic agents. The risk of neuropathy increases with cumulative exposure. The first symptoms are paresthesias, with dysesthesias occurring after a few courses of chemotherapy, and often followed by severe neuropathic pain.

The Study Chair, Professor Robert H. Dworkin stated, "I am pleased that EpiCept and the CCOP are working together to address this unmet medical need. CPN is becoming a more prevalent issue with the wider use of more active chemotherapeutic agents."

"We are excited that the NCI funded CCOP has chosen to conduct this clinical trial of EpiCept NP-1," remarked Jack Talley, President and Chief Executive Officer. "We believe the results of this study will build upon the body of clinical evidence which demonstrates the ability of NP-1 to provide long-term relief from the pain resulting from peripheral neuropathies."

The topical delivery mechanism of EpiCept NP-1 could provide important clinical advantages in treating CPN patients, including the reduction of systemic side effects and drug interactions.

The Phase III trial is expected to be initiated before the end of the third quarter of 2007. The double-blind, randomized placebo-controlled study will enroll approximately 400 patients suffering from painful CPN for at least 28 days following the conclusion of chemotherapy.

The trial will be 12 weeks in duration, with the primary endpoint being the change in average daily pain intensity scores from baseline to the end point. The secondary endpoints include the percentage of patients whose pain intensity decreases greater or equal to 30% from baseline and various other measures.

EpiCept NP-1 Clinical Development

EpiCept has initiated two additional Phase IIb trials for EpiCept NP-1, enrolling a total of 700 patients. The first trial is a 200 patient, placebo- controlled study of NP-1 in patients with diabetic peripheral neuropathy (DPN). More patients suffer from DPN than any other type of neuropathic pain. Only two medications are currently approved for this use. The trial is intended to confirm and expand upon earlier work which provided an efficacy signal in this type of neuropathic pain. The primary endpoint for this trial is the change in pain intensity over the four-week duration of the trial. Preliminary results are expected by the fourth quarter of 2007.

The second trial is a 500 patient, placebo- and active-controlled trial in peripheral herpetic neuropathy (PHN). This trial will compare the efficacy and safety of NP-1 vs. gabapentin as well as placebo. This active comparator trial is one of the first such efforts to examine any candidate compound at this scale in neuropathic pain. The primary endpoint for this trial is the change in pain intensity over the four-week duration of trial. Preliminary results are expected in the first quarter of 2008.

[nullcheck]

Antwort auf Beitrag Nr.: 30.812.778 von Der.Eroberer am 23.07.07 15:22:57

Dem Kurs hilft es trotzdem nicht, selbst Insider sind nicht auszumachen

[Scheilko]

Antwort auf Beitrag Nr.: 30.531.427 von Scheilko am 07.07.07 01:18:49

News:

EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound

http://biz.yahoo.com/prnews/070817/nyf008a.html?.v=4

[50bager]

oh keine guten news nachbörslich!

neue tiefstkurse werden kommn!

5:52PM EpiCept files $50 shelf offering in Form S-3 (EPCT) 1.59 +0.06 :

[panik]

2007-08-17
Purchase 2007-08-20
5:04 pm EPICEPT CORP EPCT SAVAGE ROBERT G
(Director) 4,000 $1.575 $6,300 4,000

[nullcheck]

Antwort auf Beitrag Nr.: 31.241.245 von panik am 21.08.07 15:45:28

Endlich wieder leben hier, 2 Postings geil, in letzter Zeit einige Umsätze gesehen und jetzt Insider wennauch nicht viel Geld gewesen.GBI ist zwar mit drin aber könnte was werden

[50bager]

gestern wieder insiderkauf!

2007-08-20
Purchase 2007-08-21
4:20 pm EPICEPT CORP EPCT SAVAGE ROBERT G
(Director) 7,500 $1.577 $11,824 11,500
(Direct

[50bager]

wieder insiderkauf!


EPICEPT SAVAGE ROBERT G (Director) B 28,600 1.60 45,652 19:21:40 2007-08-21

[panik]

EPICEPT BHAGWAT DILEEP (SVP-Pharmaceutical Development) B 1,000 1.61 1,610 16:08:10 2007-08-23

[nullcheck]

Antwort auf Beitrag Nr.: 31.288.197 von panik am 24.08.07 22:44:33

??? Über 200000 Stück aber fallende Kurse, Meldung in Presse muss wohl negativ sein kann mit Übersetzungsprogramm nichts sinnvolles herrauslesen

[nullcheck]

Antwort auf Beitrag Nr.: 31.258.594 von 50bager am 22.08.07 18:16:18

Ein paar Insiderkäufe um evtl.Kurse manipulieren und dann Pleite anzumelden,bleibe dabei egal

[50bager]

EpiCept Announces Rule 10b5-1 Trading Plans
Friday August 24, 8:15 pm ET
Replace Expired Plans Initially Adopted in 2006


TARRYTOWN, N.Y., Aug. 24 /PRNewswire-FirstCall/ -- EpiCept Corporation (Nasdaq and OMX Nordic Exchange: EPCT) announced today that on August 22, 2007 TVM III Limited Partnership ("TVM III"), TVM IV GmbH & Co. KG ("TVM IV") and Mr. John J. DiBello each entered into trading plans with Deutsche Bank Securities Inc. pursuant to Rule 10b5-1 of the Exchange Act of 1934. The Plans follow the recent expiration of similar plans that were adopted in June 2006.



(Logo: http://www.newscom.com/cgi-bin/prnh/20020513/NYM112LOGO )

Dr. Gert Caspritz, a director of the Company, is a General Partner and an Investment Manager in the healthcare and life sciences group of TVM Capital, which is the general partner of each of TVM III and TVM IV. In addition, Mr. John J. DiBello is an affiliate of the Company and a Partner of TVM Capital. Under these trading plans, the Company's stock price must reach a minimum of $4.00 per share before any of TVM III's, TVM IV's or Mr. DiBello's shares may be sold. Under these plans, each 10b5-1 plan shareholder has authorized the sale of up to the full amount of their holdings of EpiCept common stock.

Under the plans, the 10b5-1 shareholders may sell 25% of their individual holdings at a price range of $4.00 to $6.49 per share, 25% of their individual holdings at a price range of $6.50 to $8.99 per share, an additional 25% of their individual holdings at a price range of $9.00 to $11.49 per share, and the final 25% of their individual holdings at a price at or above $11.50 per share. Sales under the plans may begin on August 22, 2007, and the plans are scheduled to continue for 12 months from the date of inception.

The plans also provide that the shares are to be sold pro-rata as allowed pursuant to Rule 144 of the Securities Act of 1933. The common stock sales will occur from time to time in accordance with the trading plans and will be conducted under the direction of Deutsche Bank Securities Inc. TVM III, TVM IV and Mr. DiBello will report the sales as appropriate in filings with the Securities and Exchange Commission as required by law.

In order to maintain compliance with the rules of the OMX Nordic Stock Exchange (where, in addition to Nasdaq, the Company's securities are listed under the ticker symbol: EPCT), the plans provide that no trading shall take place during the 30-day period prior to the release of financial statements for the prior quarter, resulting in the following restricted periods: September 17, 2007 - November 16, 2007, December 18, 2007 - May 19, 2008, and June 17, 2008 - August 18, 2008; provided that the end of each restricted period shall be extended to the date of the actual public announcement of the Company's results or such later date as required by the OMX Nordic Exchange.

About EpiCept Corporation

EpiCept is focused on unmet needs in the treatment of pain and cancer. EpiCept has a staged portfolio of pharmaceutical product candidates with several pain therapies in late-stage clinical trials, and a lead oncology compound (for acute myeloid leukemia, or AML) with demonstrated efficacy in a Phase III trial; a marketing authorization application for this compound has been submitted in Europe. EpiCept is based in Tarrytown, N.Y., and its research and development team in San Diego is pursuing a drug discovery program focused on novel approaches to apoptosis.

Forward-Looking Statements

This news release and any oral statements made with respect to the information contained in this news release, contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements include statements which express plans, anticipation, intent, contingency, goals, targets, future development and are otherwise not statements of historical fact. These statements are based on EpiCept's current expectations and are subject to risks and uncertainties that could cause actual results or developments to be materially different from historical results or from any future results expressed or implied by such forward-looking statements. Factors that may cause actual results or developments to differ materially include: the risk that Ceplene will not receive regulatory approval or marketing authorization in the EU or that Ceplene, if approved, will not achieve significant commercial success, the risk that Myriad's development of Azixa will not be successful, the risk that Azixa will not receive regulatory approval or achieve significant commercial success, the risk that we will not receive any significant payments under our agreement with Myriad, the risk that the development of our other apoptosis product candidates will not be successful, the risk that our ASAP technology will not yield any successful product candidates, the risk that clinical trials for NP-1 will not be successful, that NP-1 will not receive regulatory approval or achieve significant commercial success, the risk that our other product candidates that appeared promising in early research and clinical trials do not demonstrate safety and/or efficacy in larger-scale or later stage clinical trials, the risk that EpiCept will not obtain approval to market any of its product candidates, the risks associated with reliance on additional outside financing to meet its capital requirements, the risks associated with dependence upon key personnel, the risks associated with reliance on collaborative partners and others for further clinical trials, development, manufacturing and commercialization of our product candidates; the cost, delays and uncertainties associated with our scientific research, product development, clinical trials and regulatory approval process; our history of operating losses since our inception; competition; litigation; risks associated with prior material weaknesses in our internal controls; and risks associated with our ability to protect our intellectual property. These factors and other material risks are more fully discussed in EpiCept's periodic reports, including its reports on Forms 8-K, 10-Q and 10-K and other filings with the U.S. Securities and Exchange Commission. You are urged to carefully review and consider the disclosures found in EpiCept's filings which are available at www.sec.gov or at www.epicept.com. You are cautioned not to place undue reliance on any forward-looking statements, any of which could turn out to be wrong due to inaccurate assumptions, unknown risks or uncertainties or other risk factors.

EPCT-GEN




--------------------------------------------------------------------------------
Source: EpiCept Corporation

[nullcheck]

Antwort auf Beitrag Nr.: 31.289.851 von 50bager am 25.08.07 10:58:37

Auch gelesen aber kann damit nichts anfangen kannst du mir helfen?

[nullcheck]

Antwort auf Beitrag Nr.: 31.290.025 von nullcheck am 25.08.07 11:37:17

Habe mal 10b5-1 eingegeben hat was mit verbotenen? Insiderhandel zu tun vielleicht lag ich mit meiner Behauptung nicht so verkehrt ,Oder?

[nullcheck]

Antwort auf Beitrag Nr.: 31.241.245 von panik am 21.08.07 15:45:28

Mann brech nicht gleich in Panik aus 6300 Dollar,toll

[nullcheck]

Antwort auf Beitrag Nr.: 31.290.343 von nullcheck am 25.08.07 13:06:34

Dieser Thread ist mit grossen Abstand das letzte bei Wo ,hier erfährt man nichts neues, Heckenpennerthread stimmt immer noch!!!!!!

[50bager]

nullcheck
du machst deinen namen aller ehre!

verkauf deine aktien...du hast dann deine ruhe!

wenn du der sprache nicht mächtig bist... solltest du keine aktien kaufen!

[nullcheck]

Antwort auf Beitrag Nr.: 31.297.705 von 50bager am 26.08.07 21:30:53

Spiele auch nicht den Wissenden wie mancher Möchtegern,ist Epicept eine Aktie ? wohl eher ein Zockerpapier,ist auch nur Spielgeld

[50bager]

möchtegern spielen???

[nullcheck]

Antwort auf Beitrag Nr.: 31.301.265 von 50bager am 27.08.07 11:54:42

Muss für Sie wohl eine Zeichnung nachreichen,aber werden Sie auch nicht lesen können

[panik]

EPICEPT BHAGWAT DILEEP (SVP-Pharmaceutical Development) B 1,500 1.60 2,400 11:10:28 2007-08-24

[nullcheck]

Antwort auf Beitrag Nr.: 31.305.263 von panik am 27.08.07 17:21:42

Die Käufer schlagen sich, schon wieder 2400E aber eine Meldung wert

[Scheilko]

Antwort auf Beitrag Nr.: 31.305.263 von panik am 27.08.07 17:21:42

Insider Transaction Details For EPCT
August 23, 2007 - 400 Shares - Buy
BHAGWAT DILEEP Senior Vice President-Pharmaceutical Development
Share Price: $1.60Transaction Value: $640.0Open market or private purchase of non-derivative security reported on 08/23/07
August 23, 2007 - 600 Shares - Buy
BHAGWAT DILEEP Senior Vice President-Pharmaceutical Development
Share Price: $1.62Transaction Value: $972.0Open market or private purchase of non-derivative security reported on 08/23/07
August 21, 2007 - 6,100 Shares - Buy
SAVAGE ROBERT G Director
Share Price: $1.61Transaction Value: $9.8KOpen market or private purchase of non-derivative security reported on 08/21/07
August 21, 2007 - 3,000 Shares - Buy
SAVAGE ROBERT G Director
Share Price: $1.60Transaction Value: $4.8KOpen market or private purchase of non-derivative security reported on 08/21/07
August 21, 2007 - 3,000 Shares - Buy
SAVAGE ROBERT G Director
Share Price: $1.59Transaction Value: $4.8KOpen market or private purchase of non-derivative security reported on 08/21/07
August 21, 2007 - 7,000 Shares - Buy
SAVAGE ROBERT G Director
Share Price: $1.58Transaction Value: $11.1KOpen market or private purchase of non-derivative security reported on 08/21/07
August 21, 2007 - 3,000 Shares - Buy
SAVAGE ROBERT G Director
Share Price: $1.56Transaction Value: $4.7KOpen market or private purchase of non-derivative security reported on 08/21/07
August 21, 2007 - 2,200 Shares - Buy
SAVAGE ROBERT G Director
Share Price: $1.61Transaction Value: $3.5KOpen market or private purchase of non-derivative security reported on 08/21/07
August 21, 2007 - 2,300 Shares - Buy
SAVAGE ROBERT G Director
Share Price: $1.61Transaction Value: $3.7KOpen market or private purchase of non-derivative security reported on 08/21/07
August 21, 2007 - 2,000 Shares - Buy
SAVAGE ROBERT G Director
Share Price: $1.61Transaction Value: $3.2KOpen market or private purchase of non-derivative security reported on 08/21/07
August 20, 2007 - 1,000 Shares - Buy
SAVAGE ROBERT G Director
Share Price: $1.59Transaction Value: $1.6KOpen market or private purchase of non-derivative security reported on 08/20/07
August 20, 2007 - 500 Shares - Buy
SAVAGE ROBERT G Director
Share Price: $1.58Transaction Value: $790.0Open market or private purchase of non-derivative security reported on 08/20/07
August 20, 2007 - 500 Shares - Buy
SAVAGE ROBERT G Director
Share Price: $1.57Transaction Value: $785.0Open market or private purchase of non-derivative security reported on 08/20/07
August 20, 2007 - 800 Shares - Buy
SAVAGE ROBERT G Director
Share Price: $1.58Transaction Value: $1.3KOpen market or private purchase of non-derivative security reported on 08/20/07
August 20, 2007 - 1,000 Shares - Buy
SAVAGE ROBERT G Director
Share Price: $1.57Transaction Value: $1.6KOpen market or private purchase of non-derivative security reported on 08/20/07
August 20, 2007 - 700 Shares - Buy
SAVAGE ROBERT G Director
Share Price: $1.58Transaction Value: $1.1KOpen market or private purchase of non-derivative security reported on 08/20/07
August 20, 2007 - 1,000 Shares - Buy
SAVAGE ROBERT G Director
Share Price: $1.57Transaction Value: $1.6KOpen market or private purchase of non-derivative security reported on 08/20/07
August 20, 2007 - 900 Shares - Buy
SAVAGE ROBERT G Director
Share Price: $1.58Transaction Value: $1.4KOpen market or private purchase of non-derivative security reported on 08/20/07
August 20, 2007 - 1,100 Shares - Buy
SAVAGE ROBERT G Director
Share Price: $1.57Transaction Value: $1.7KOpen market or private purchase of non-derivative security reported on 08/20/07
August 17, 2007 - 500 Shares - Buy
SAVAGE ROBERT G Director
Share Price: $1.59Transaction Value: $795.0Open market or private purchase of non-derivative security reported on 08/17/07
August 17, 2007 - 1,000 Shares - Buy
SAVAGE ROBERT G Director
Share Price: $1.58Transaction Value: $1.6KOpen market or private purchase of non-derivative security reported on 08/17/07
August 17, 2007 - 2,500 Shares - Buy
SAVAGE ROBERT G Director
Share Price: $1.57Transaction Value: $3.9KOpen market or private purchase of non-derivative security reported on 08/17/07

[panik]

EPICEPT Talley John V (President, CEO & Director) B 10,000 1.64 16,450 11:50:32 2007-08-28

[nullcheck]

Antwort auf Beitrag Nr.: 31.318.840 von panik am 28.08.07 18:16:45

Bist du im englischsprachigen Raum beheimatet oder warum kommen von Dir eigentlich nur englische Texte die auch nur abgeschrieben sind und auch jeder selber findet. Du hast den Thread eröffnet bring mal was außer Portokassenkäufe

[nullcheck]

Antwort auf Beitrag Nr.: 31.322.073 von nullcheck am 28.08.07 21:20:03

Hi Panik hast du die 3 Stück gekauft oder wer von euch wissenden??

[50bager]

[nullcheck]

Antwort auf Beitrag Nr.: 31.338.859 von 50bager am 30.08.07 10:26:08

Epi wird mein dritter 1000%er aber was willst du mit dem Chart sagen??

[panik]

EPICEPT COOK ROBERT W (CFO-SVP, Finance & Admin.) B 1,803 1.69 3,047 16:39:29 2007-08-30
COOK ROBERT W (CFO-SVP, Finance & Admin.) B 8,197 1.66 13,607 16:39:29 2007-08-29

[50bager]

weiterhin insiderkäufe

Last 52 Wks: 02-Sep-06 - 31-Aug-07
$100.88K Buy: 4
Sell: 0 $100.88K
($0) $1.57 - $1.69
--
Previous 52 Wks: 03-Sep-05 - 01-Sep-06
$13.50K Buy: 1
Sell: 0 $13.50K
($0) $2.70
--
Change
$87.38K Buy: +3
Sell: 0 $87.38K
$0





C-Level Officers 2
$33.14K $0 $33.14K
Cook Robert W
CFO-SVP, Finance & Admin. $16.65K $0 $16.65K
Talley John V
President, CEO & Director $16.49K $0 $16.49K
Other Officers 1
$4.01K $0 $4.01K
Bhagwat Dileep
SVP-Pharmaceutical Development $4.01K $0 $4.01K
Directors 2
$63.72K $13.50K $50.22K

Yesterday 4:39 PM
View: Cook Robert W
CFO-SVP, Finance & Admin. -- Yesterday Market Purchase
(1,803 @ $1.69) $3,047.11 22% -0% (< 1mo)
Yesterday 4:39 PM
View: Cook Robert W
CFO-SVP, Finance & Admin. -- 29-Aug-07 Market Purchase
(8,197 @ $1.66) $13,607.02 100% --
28-Aug-07 11:50 AM
View: Talley John V
President, CEO & Director
Director -- 28-Aug-07 Market Purchase
(10,000 @ $1.65) $16,489.00 11% --
27-Aug-07 11:10 AM
View: Bhagwat Dileep
SVP-Pharmaceutical Development -- 24-Aug-07 Market Purchase
(1,500 @ $1.60) $2,400.00 150% --
24-Aug-07 4:08 PM
View: Bhagwat Dileep
SVP-Pharmaceutical Development -- 23-Aug-07 Market Purchase
(1,000 @ $1.61) $1,612.00 100% --
22-Aug-07 7:21 PM
View: Savage Robert G
Director -- 21-Aug-07 Market Purchase
(6,500 @ $1.61) $10,465.00 5% --
22-Aug-07 7:21 PM
View: Savage Robert G
Director -- 21-Aug-07 Market Purchase
(22,100 @ $1.59) $35,131.04 19% --
21-Aug-07 4:20 PM
View: Savage Robert G
Director -- 20-Aug-07 Market Purchase
(5,500 @ $1.57) $8,658.98 19% --
21-Aug-07 4:20 PM
View: Savage Robert G
Director -- 20-Aug-07 Market Purchase
(2,000 @ $1.58) $3,165.00 7% --
20-Aug-07 5:04 PM
View: Savage Robert G
Director -- 17-Aug-07 Market Purchase
(4,000 @ $1.58) $6,300.00 100% --
15-Jun-06 12:31 AM
View: Jackson Guy C
Director -13%
(7 decisions) 13-Jun-06 Market Purchase
(5,000 @ $2.70) $13,497.00 100% -19% (1yr)

[50bager]

EPICEPT Bedard John F (Director) B 2,000 1.68 3,360 17:02:13 2007-09-04

[Scheilko]

Schöne Zusammenstellung der zu erwartenden Ereignisse 2007 bzw. 2008
(Gefunden auf dem Yahoo Board von Mr. „alesto12“)


1.Ceplene 120 days protocol EMEA Q3 2007
2.Decision EMEA Q1 2008
3. NP-1 CPN phase III-studie Q3 2007
4. EPC2407 phase Ib-studie, data phase I Q4 2007
5.NP-1 DPN fas IIb-study results Q4 2007
6.NP-1 PHN fas IIb-study results Q1 2008
7.Azixa data phase II studies H1 2008
8.NDA study H2 2008
9.LidoPainBP phase III-studie Q4 2007/Q1 2008
10.LidoPainSP phase III-studie H1 2008
11. Milestone payments Azixa Q3 2007

[Scheilko]

Antwort auf Beitrag Nr.: 31.536.943 von Scheilko am 11.09.07 20:19:53

Wieder ein Stück weiter!
http://biz.yahoo.com/prnews/070918/nytu063.html?.v=101

http://files.shareholder.com/downloads/EPCT/169945390x0x1321…

[nullcheck]

Antwort auf Beitrag Nr.: 31.640.266 von Scheilko am 18.09.07 09:50:13

Aber aus 5% Plus wird am Ende nur 1%

[nullcheck]

watten keine Insiders mehr die sich keine 1000 Stück mehr leisten können ??

[nullcheck]

Antwort auf Beitrag Nr.: 31.746.216 von nullcheck am 26.09.07 11:00:26

Gute Nachricht!!

[nullcheck]

Antwort auf Beitrag Nr.: 31.895.454 von nullcheck am 08.10.07 09:45:58

Na liegt ihr alle wieder hinter der Hecke und pennt?

[50bager]

Ja nullcheck

Habe mir weiter zu 1,60$ EPCT aufgestockt

[Scheilko]

News aus Schweden bezüglich Ceplene.

Sieht soweit ganz gut aus...

http://di.se/Nyheter/?page=%2fAvdelningar%2fArtikel.aspx%3fO…

[nullcheck]

Antwort auf Beitrag Nr.: 32.288.187 von 50bager am 05.11.07 11:37:01

ich leider zu früh, auf finanznachrichten .de aktuelles in English wer kann schwedisch?

[50bager]

insider schlagen wieder zu!

2007-12-12
Purchase 2007-12-14
1:45 pm EPICEPT CORP EPCT BHAGWAT DILEEP
(SVP-Pharmaceutical Development) 10,000 $1.427 $14,275 12,500
(Direct) View
2007-09-13-
-2007-12-12
Purchase 2007-12-13
5:08 pm EPICEPT CORP EPCT ALLARD STEPHANE
(Chief Medical Officer) 45,600 $1.428 $65,104 45,600
(Direct
Indirect) View
2007-12-13
Purchase 2007-12-13
3:59 pm EPICEPT CORP EPCT Talley John V
(President, CEO & Director
Director) 15,000 $1.4 $21,000 117,146
(Direct) View
2007-12-13
Purchase 2007-12-13
3:57 pm EPICEPT CORP EPCT COOK ROBERT W
(CFO-SVP, Finance & Admin.) 5,000 $1.35 $6,750 15,000
(Direct) View
2007-09-04
Purchase 2007-09-04
5:02 pm EPICEPT CORP EPCT Bedard John F
(Director) 2,000 $1.68 $3,360 2,000
(Direct) View
2007-08-29-
-2007-08-30
Purchase 2007-08-30
4:39 pm EPICEPT CORP EPCT COOK ROBERT W
(CFO-SVP, Finance & Admin.) 10,000 $1.665 $16,654 10,000
(Direct) View
2007-08-28
Purchase 2007-08-28
11:50 am EPICEPT CORP EPCT Talley John V
(President, CEO & Director
Director) 10,000 $1.649 $16,489 102,146
(Direct) View
2007-08-24
Purchase 2007-08-27
11:10 am EPICEPT CORP EPCT BHAGWAT DILEEP
(SVP-Pharmaceutical Development) 1,500 $1.6 $2,400 2,500
(Direct) View
2007-08-23
Purchase 2007-08-24
4:08 pm EPICEPT CORP EPCT BHAGWAT DILEEP
(SVP-Pharmaceutical Development) 1,000 $1.612 $1,612 1,000
(Direct) View
2007-08-21
Purchase 2007-08-22
7:21 pm EPICEPT CORP EPCT SAVAGE ROBERT G
(Director) 28,600 $1.594 $45,596 40,100
(Direct
Indirect) View
2007-08-20
Purchase 2007-08-21
4:20 pm EPICEPT CORP EPCT SAVAGE ROBERT G
(Director) 7,500 $1.577 $11,824 11,500
(Direct
Indirect) View
2007-08-17
Purchase 2007-08-20
5:04 pm EPICEPT CORP EPCT SAVAGE ROBERT G
(Director) 4,000 $1.575 $6,300 4,000
(Direct

[nullcheck]

Antwort auf Beitrag Nr.: 32.769.968 von 50bager am 14.12.07 20:12:46

Den letzten Meldungen zufolge müsste der Kurs höher stehen tut,s aber nicht,warum weil wohl kein vertrauen in der Aktie reinkommt. Habe nachgekauft ,verbilligt?? Die Insiderkäufe überzeugen eigentlich nicht dafür ist die Summe zu klein,aber wenn di euns nicht die Hucke volllügen muss es nach oben gehen und das bis min. 4 US D.

[50bager]

Epicept der nächste Vervielfacher?


http://reboundhotstocks.blogspot.com/2008/01/epicept-der-nch…

[nullcheck]

!

Dieser Beitrag wurde moderiert. Grund: Fäkalsprache

[nullcheck]

Antwort auf Beitrag Nr.: 32.989.629 von 50bager am 09.01.08 10:14:37

Tut sich was?

[nullcheck]

Antwort auf Beitrag Nr.: 33.278.589 von nullcheck am 05.02.08 22:48:08

Wo sind wir hier ,klar Hpt

[nullcheck]

Antwort auf Beitrag Nr.: 33.290.389 von nullcheck am 06.02.08 23:00:45

raus mit dem scheiß

[nullcheck]

Antwort auf Beitrag Nr.: 33.503.331 von nullcheck am 28.02.08 14:35:43

das war Maßarbeit muhahaha ihr Hptler

[kevin.lomax]

Press Release Source: EpiCept Corporation


[urlEpiCept Announces Pricing of Public Offering]http://biz.yahoo.com/bw/080624/20080623006393.html?.v=1
[/url]

Tuesday June 24, 12:01 am ET

TARRYTOWN, N.Y.--(BUSINESS WIRE)--Regulatory News:



EpiCept Corporation (Nasdaq and OMX Nordic Exchange: EPCT) announced today the pricing of a public offering of approximately 8 million shares of its common stock at $.25 per share and five-year warrants to purchase up to approximately 8 million shares of common stock at an exercise price of $.39 per share. EpiCept will receive approximately $1.9 million in net proceeds from the offering. Rodman & Renshaw, LLC, a subsidiary of Rodman & Renshaw Capital Group, Inc. (Nasdaq: RODM - News) acted as the exclusive placement agent for the offering. EpiCept intends to use the net proceeds it receives to meet its working capital needs and general corporate purposes through July 2008 and to pay certain fees owed to its senior secured lender.



The proposed public offering is being made pursuant to an effective registration statement, and may be made only by means of a prospectus and prospectus supplement. A copy of the preliminary prospectus supplement relating to the common stock and warrants can be obtained from Rodman & Renshaw LLC, 1270 Avenue of the Americas, New York, NY 10020, or by calling 212-356-0549.



An electronic copy of the preliminary prospectus supplement will also be available on the website of the Securities and Exchange Commission (the “SEC”) at http://www.sec.gov.



This press release is neither an offer to sell, nor a solicitation of an offer to buy, nor shall there be any sale of, these securities in any state in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state.

About EpiCept Corporation

EpiCept is focused on unmet needs in the treatment of pain and cancer. The Company’s broad portfolio of pharmaceutical product candidates includes several pain therapies in clinical development and a lead oncology compound for AML with demonstrated efficacy in a Phase III trial. In addition, EpiCept’s ASAP technology, a proprietary live cell high-throughput caspase-3 screening technology, can efficiently identify new cancer drug candidates and molecular targets that selectively induce apoptosis in cancer cells. Two oncology drug candidates currently in clinical development that were discovered using this technology have also been shown to act as vascular disruption agents in a variety of solid tumors.

Forward-Looking Statements

This news release and any oral statements made with respect to the information contained in this news release, contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements include statements which express plans, anticipation, intent, contingency, goals, targets, future development and are otherwise not statements of historical fact. These statements are based on EpiCept's current expectations and are subject to risks and uncertainties that could cause actual results or developments to be materially different from historical results or from any future results expressed or implied by such forward-looking statements. Factors that may cause actual results or developments to differ materially include: the risk that the proposed public offering will not be consummated, the risks associated with the adequacy of our existing cash resources and our need to raise additional financing to continue to meet our capital needs and our ability to continue as a going concern, the risks associated with our ability to continue to meet our obligations under our existing debt agreements or that we may default on our loans or that our lenders may declare the Company in default or that our secured lender would seek to sell our assets, the risk that the Company's securities may be delisted by The Nasdaq Capital Market or the OMX Nordic Exchange and that any appeal of the delisting determination may not be successful, the risk that our appeal of the negative opinion regarding the MAA for Ceplene(R) will not be successful and that Ceplene(R) will not receive regulatory approval or marketing authorization in the EU, the risk that Ceplene(R), if approved, will not achieve significant commercial success, the risk that Myriad's development of Azixa(TM) will not be successful, the risk that Azixa(TM) will not receive regulatory approval or achieve significant commercial success, the risk that we will not receive any significant payments under our agreement with Myriad, the risk that the development of our other apoptosis product candidates will not be successful, the risk that our ASAP technology will not yield any successful product candidates, the risk that clinical trials for NP-1 or EPC2407 will not be successful, the risk that NP-1 or EPC2407 will not receive regulatory approval or achieve significant commercial success, the risk that our other product candidates that appeared promising in early research and clinical trials do not demonstrate safety and/or efficacy in larger-scale or later stage clinical trials, the risk that we will not obtain approval to market any of our product candidates, the risks associated with dependence upon key personnel, the risks associated with reliance on collaborative partners and others for further clinical trials, development, manufacturing and commercialization of our product candidates; the cost, delays and uncertainties associated with our scientific research, product development, clinical trials and regulatory approval process; our history of operating losses since our inception; the highly competitive nature of our business; risks associated with litigation; risks associated with prior material weaknesses in our internal controls; and risks associated with our ability to protect our intellectual property. These factors and other material risks are more fully discussed in EpiCept's periodic reports, including its reports on Forms 8-K, 10-Q and 10-K and other filings with the U.S. Securities and Exchange Commission. You are urged to carefully review and consider the disclosures found in EpiCept's filings, which are available at www.sec.gov or at www.epicept.com. You are cautioned not to place undue reliance on any forward-looking statements, any of which could turn out to be wrong due to inaccurate assumptions, unknown risks or uncertainties or other risk factors.

EPCT-GEN


*Azixa is a registered trademark of Myriad Genetics, Inc.

[Fruehrentner]

pennt ihr?


EpiCept's leukemia drug recommended for approval in EU
25th July 2008

EpiCept Corporation has announced that the Committee for Medicinal Products for Human Use of the European Medicines Agency has issued a positive opinion regarding the marketing authorization for Ceplene, for the remission maintenance and prevention of relapse in adult patients with acute myeloid leukemia in first remission.
Ceplene is to be administered in conjunction with low-dose interleukin-2 (IL-2). This positive opinion was issued following a request made by EpiCept to have the initial negative opinion of March 2008 re-examined by the CHMP. Ceplene has been designated as an orphan medicinal product, and as such is entitled to 10 years of marketing exclusivity in the EU.

Following the oral explanation from EpiCept, the CHMP recommended that Ceplene be granted a full marketing authorization under the provision of exceptional circumstances.

As part of granting of the marketing authorization under exceptional circumstances, EpiCept has agreed to perform two post-approval clinical studies. One of the studies seeks to further elucidate the clinical pharmacology of Ceplene by assessing certain biomarkers in AML patients in first remission.

The other study will assess the effect of Ceplene/IL-2 on the development of minimal residual disease in the same patient population. EpiCept is entitled to seek further guidance on the design of such studies from the EMEA through the protocol assistance procedure.

The CHMP's recommendation will now be forwarded to the European Commission for issuing a marketing authorization in the form of a Commission decision, which normally occurs within 67 days. The marketing authorization with unified clinical usage for Ceplene granted under the centralized procedure will be valid for the entire EU as well as in Iceland, Liechtenstein and Norway.

[Fruehrentner]

Antwort auf Beitrag Nr.: 34.598.016 von Fruehrentner am 28.07.08 14:02:07

http://www.pharmaceutical-business-review.com/article_news.a…

[Fruehrentner]

[Scheilko]

Wednesday, September 17, 2008
Epicept, EPCT, Preparing for Ceplene Launch in Europe
In a recent Press Release, Epicept Corporation (EPCT) just announced that the company has ammended it's December 20, 2006 licensing agreement with DURECT Corporation granting DURECT exclusive, worldwide rights to certain EpiCept intellectual property for a transdermal patch containing bupivacaine for the treatment of back pain.

The terms of the amendment, as outlined in the PR:
Under the terms of the amended agreement, EpiCept has granted DURECT royalty-free, fully paid up, perpetual and irrevocable rights to the intellectual property licensed as part of the original agreement in exchange for a cash payment of USD 2.25million from DURECT.

It looks like Epicept took the cash from this lecensing agreement as an alternative to further dilution of the stock. The stock has been diluted a couple of times since the drop into the thirty cent range. The decision to take the cash from the licensing agreement will carry the company over until the upcoming Ceplene news.
The company anticipates a final marketing authorization from the EMEA for Ceplene sometime in the next several weeks.

Ceplene's path to marketing authorization in Europe has been a roller coaster ride that currently has EPCT trading in the sixty cent range, but earlier this year the stock had been trading in the thirty cent range following a negative trend vote by the EMEA regarding the marketing authorization for Ceplene. Upon review, the EMEA reversed their decision, but the reversal did not instill a whole lot of confidence in investors, as the stock continues to trade under a buck.

EPCT is currently one of my favorites. The risk reward for this stock right now is laughable. If Ceplene receives the marketing authorization in a few weeks, the stock should double almost immediately, to be followed by some profit taking, then an uptrend leading to much higher gains next year. If Ceplene does not receive the marketing approval then the stock will be cut in half, but the company would still have five drugs in the pipeline, including Azixa, that could rebound the stock in a big way down the line.

EPCT is by no means a one trick pony.

$9.95 Telephone Service
Phone Power: No Activation Fee
No Contract, $9.95mo Unlimited Use

Azixa, the company's drug to combat cancerous metastatic tumours, showed promising results during a Phase I trial tailored to treatbrain cancer. The stock has reached nearly five dollars on updates of this drug alone. Epicept has a licensing agreement with Myriad in which Myriad takes care of most of the legwork regarding Azixa's trials, production and marketing, while Epicept will receive milestone payments and a percentage of sales. Azixa is a promising candidate to look to if Ceplene fails. For now, however, the real news regarding EPCT falls with Ceplene.
http://vfcsstockhouse.blogspot.com/2008/09/epicept-epct-prep…

[schmacki]

Press Release Source: EpiCept Corporation

EpiCept Receives Ceplene(R) Marketing Approval in Europe
Thursday October 9, 12:01 am ET

TARRYTOWN, N.Y.--(BUSINESS WIRE)--Regulatory News:

EpiCept Corporation (Nasdaq and OMX Nordic Exchange: EPCT) today announced that the European Commission has granted a full marketing authorization in the form of a positive Commission Decision, for Ceplene® (histamine dihydrochloride) for the remission maintenance and prevention of relapse in adult patients with Acute Myeloid Leukemia (AML) in first remission. Ceplene is to be administered in conjunction with low-dose interleukin-2 (IL-2). The approval allows Ceplene to be marketed in the 27 member states of the European Union (EU), as well as in Iceland, Liechtenstein and Norway.

ADVERTISEMENT
“Today marks a significant and welcome milestone for patients suffering from AML,” stated Jack Talley, president and CEO of EpiCept. “Ceplene is now the first approved therapy demonstrated to produce a clear benefit in prolonging leukemia-free survival and preventing relapse among AML patients. We are proud that this new therapeutic option will be available to physicians and patients in 30 countries.”

The approval by the European Commission is based, in part, on the results of the pivotal 320-patient Phase III trial for Ceplene in conjunction with IL-2. The primary result of this trial was that treatment with Ceplene/IL-2 significantly reduced the occurrence of relapse among AML patients in complete remission. The improvement of long-term leukemia-free survival in patients receiving Ceplene/IL-2 exceeded 50%. Moreover, Ceplene was well tolerated in this patient population and conferred an acceptable risk benefit profile for AML patients.

“The main challenge in AML treatment is to protect patients in their first complete remission from relapse, as a first relapse is associated with poor long-term survival. The combination of Ceplene and IL-2 has been demonstrated to be a safe therapy that improves leukemia-free survival by significantly reducing the risk of recurrent leukemia. Therefore, the approval granted for Ceplene is an important step forward in making the treatment available to AML patients,” said Mats Brune, M.D., associate professor at Sahlgrenska University and principal investigator of the Ceplene Phase III clinical trial.

“Ceplene improves the capacity of the patients’ immune cells to attack and destroy malignant cells,” said Kristoffer Hellstrand, M.D., Ph.D., professor at the University of Gothenburg, Sweden and the discoverer of the Ceplene technology. “Ceplene/IL-2 therapy is intended to eliminate residual AML cells, which are the cause of relapse in AML patients.”

As a result of its designation as an Orphan Medical Product, EpiCept has been granted 10 years of market exclusivity in the EU for Ceplene. As part of receiving marketing authorization under Exceptional Circumstances for Ceplene, EpiCept will perform two post-approval clinical studies. One of the studies will seek to further elucidate the clinical pharmacology of Ceplene by assessing certain biomarkers in AML patients in first remission. The other study will assess the effect of Ceplene/IL-2 on the development of minimal residual disease in the same patient population. EpiCept is considering combining these studies into a single clinical trial.

Mr. Talley continued: “Several potential commercial partners with established sales infrastructures in hematology and oncology in Europe have expressed interest in marketing Ceplene and are in various stages of due diligence. We expect to share further details on our commercialization strategy later this year.”

EpiCept has also advanced its efforts to gain approval for Ceplene as a remission maintenance treatment for AML patients in North America. A pre-New Drug Submission meeting with Health Canada has been scheduled during the fourth quarter of 2008, and will be followed in the first quarter of 2009 by a pre-New Drug Application meeting with the United States Food and Drug Administration.

About Ceplene

Ceplene is EpiCept's proprietary product approved for the treatment of AML. Ceplene is designed to protect lymphocytes responsible for immune-mediated destruction of residual leukemic cells. Laboratory research has demonstrated that Ceplene reduces formation of oxygen radicals from phagocytes, inhibiting NADPH oxidase and protecting IL-2-activated NK-cells and T-cells.

About Acute Myeloid Leukemia (AML)

AML is the most common type of leukemia in adults. There are approximately 40,000 AML patients in the EU, with 16,000 new cases occurring each year. Once diagnosed with AML, patients typically receive induction and consolidation chemotherapy, with the majority achieving complete remission. However, about 70-80% of patients who achieve first remission will relapse, with the median time in remission before relapse being only 12 months. Less than 15% of relapsed patients survive long-term.

About EpiCept Corporation

EpiCept is focused on unmet needs in the treatment of cancer and pain. The Company's broad portfolio of pharmaceutical product candidates includes Ceplene, a cytokine immunomodulator that recently received marketing authorization in Europe for the remission maintenance of AML patients, and several pain therapies in clinical development. In addition, EpiCept's ASAP technology, a proprietary live cell high-throughput caspase-3 screening technology, can efficiently identify new cancer drug candidates and molecular targets that selectively induce apoptosis in cancer cells. Two oncology drug candidates currently in clinical development that were discovered using this technology have also been shown to act as vascular disruption agents in a variety of solid tumors.

Forward-Looking Statements

This news release and any oral statements made with respect to the information contained in this news release, contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements include statements which express plans, anticipation, intent, contingency, goals, targets, future development and are otherwise not statements of historical fact. These statements are based on EpiCept's current expectations and are subject to risks and uncertainties that could cause actual results or developments to be materially different from historical results or from any future results expressed or implied by such forward-looking statements. Factors that may cause actual results or developments to differ materially include: the risk that Ceplene will not be launched in Europe in the first quarter of 2009 or achieve significant commercial success, the risk that we are unable to find a suitable marketing partner for Ceplene on attractive terms, a timely basis or at all, the risk that any post-approval clinical study will not be successful, the risk that EpiCept will not be able to maintain its final regulatory approval or marketing authorization, the risk that Myriad’s development of Azixa™ will not be successful, the risk that Azixa will not receive regulatory approval or achieve significant commercial success, the risk that we will not receive any significant payments under our agreement with Myriad, the risk that the development of our other apoptosis product candidates will not be successful, the risk that our ASAP technology will not yield any successful product candidates, the risk that clinical trials for NP-1 or EPC2407 will not be successful, the risk that NP-1 or EPC2407 will not receive regulatory approval or achieve significant commercial success, the risk that our other product candidates that appeared promising in early research and clinical trials do not demonstrate safety and/or efficacy in larger-scale or later stage clinical trials, the risks associated with the adequacy of our existing cash resources, our need to raise additional financing to continue to meet our capital needs and our ability to continue as a going concern, the risks associated with our ability to continue to meet our obligations under our existing debt agreements or that we may default on our loans or that our lenders may declare the Company in default, the risk that we will not obtain approval to market any of our product candidates other than Ceplene®, the risk that the Company’s securities may be delisted by The Nasdaq Capital Market or the OMX Nordic Exchange, the risks associated with dependence upon key personnel, the risks associated with reliance on collaborative partners and others for further clinical trials, development, manufacturing and commercialization of our product candidates; the cost, delays and uncertainties associated with our scientific research, product development, clinical trials and regulatory approval process; our history of operating losses since our inception; the highly competitive nature of our business; risks associated with litigation; risks associated with prior material weaknesses in our internal controls; and risks associated with our ability to protect our intellectual property. These factors and other material risks are more fully discussed in EpiCept’s periodic reports, including its reports on Forms 8-K, 10-Q and 10-K and other filings with the U.S. Securities and Exchange Commission. You are urged to carefully review and consider the disclosures found in EpiCept’s filings, which are available at www.sec.gov or at www.epicept.com. You are cautioned not to place undue reliance on any forward-looking statements, any of which could turn out to be wrong due to inaccurate assumptions, unknown risks or uncertainties or other risk factors.

EPCT-GEN

*Azixa is a registered trademark of Myriad Genetics, Inc.

[schmacki]